33 results on '"G Ibáñez-Sanz"'
Search Results
2. P251 RAID Dx: the first test based on faecal microbiota to differentiate irritable bowel syndrome from inflammatory bowel diseases
- Author
-
C Puig-Amiel, J Serra, Jordi Guardiola, Lia Oliver, F Mearin, Anna Bahí, Ingrid Marín, Ariadna Clos, J O Miquel-Cusachs, David Busquets, Miriam Sàbat, E. Domènech, Paola Torres, Míriam Mañosa, G Ibáñez-Sanz, Pau Gilabert, Leyanira Torrealba, L J Garcia-Gil, Mariona Serra-Pagès, Xavier Aldeguer, Fiorella Cañete, Joan Amoedo, and Sara Ramió-Pujol
- Subjects
medicine.medical_specialty ,business.industry ,RAID ,Gastroenterology ,Inflammatory Bowel Diseases ,General Medicine ,medicine.disease ,law.invention ,law ,Internal medicine ,medicine ,business ,Irritable bowel syndrome - Published
- 2019
3. FACTORES ASOCIADOS CON UN RESULTADO FALSO POSITIVO EN EL CRIBADO DE CÁNCER COLORRECTAL
- Author
-
Carmen Vidal, Francisco Rodríguez-Moranta, Montse Garcia, G Ibáñez-Sanz, J Gómez-Matas, A Soriano, Victor Moreno, Gemma Binefa, Xènia Domènech, and Núria Milà
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Gastroenterology ,medicine ,business - Published
- 2015
4. FALSOS NEGATIVOS DEL CRIBADO DE CÁNCER COLORRECTAL MEDIANTE TEST DE SANGRE OCULTA EN HECES Y COLONOSCOPIA COMO PRUEBA DIAGNÓSTICA
- Author
-
Montse Garcia, J Gómez-Matas, Joan B. Gornals, Victor Moreno, Gemma Binefa, G Ibáñez-Sanz, Francisco Rodríguez-Moranta, Núria Milà, Llúcia Benito, and I Padrol
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Gastroenterology ,medicine ,business - Published
- 2015
5. P213 RAID-IBS Diagnosis: A new non-invasive method to support Irritable Bowel Syndrome diagnosis
- Author
-
J O Miquel-Cusachs, Jordi Guardiola, Lia Oliver, Xavier Aldeguer, David Busquets, Míriam Mañosa, G Ibáñez-Sanz, Joan Amoedo, Pau Gilabert, Fiorella Cañete, E. Domènech, Mariona Serra-Pagès, Sara Ramió-Pujol, Anna Bahí, Leyanira Torrealba, F Mearin, Ariadna Clos, L J Garcia-Gil, and Miriam Sàbat
- Subjects
medicine.medical_specialty ,RAID ,law ,business.industry ,Internal medicine ,Non invasive ,Gastroenterology ,medicine ,General Medicine ,business ,medicine.disease ,Irritable bowel syndrome ,law.invention - Published
- 2018
6. Effectiveness and Acceptability of Targeted Text Message Reminders in Colorectal Cancer Screening: Randomized Controlled Trial (M-TICS Study).
- Author
-
Vives N, Travier N, Farre A, Binefa G, Vidal C, Pérez Lacasta MJ, Ibáñez-Sanz G, Niño de Guzmán EP, Panera JA, and Garcia M
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Spain, Patient Acceptance of Health Care statistics & numerical data, Occult Blood, Text Messaging statistics & numerical data, Colorectal Neoplasms diagnosis, Reminder Systems, Early Detection of Cancer methods
- Abstract
Background: Mobile phone-based SMS text message reminders have the potential to improve colorectal cancer screening participation rates., Objective: This study assessed the effectiveness and acceptability of adding targeted SMS text message reminders to the standard procedure for those who picked up but did not return their screening kit at the pharmacy within 14 days in a colorectal cancer screening program in Catalonia, Spain., Methods: We performed a randomized control trial among individuals who picked up a fecal immunochemical test (FIT) kit for colorectal cancer screening at the pharmacy but did not return it within 14 days. The intervention group (n=4563) received an SMS text message reminder on the 14th day of kit pick up and the control group (n=4806) received no reminder. A 30-day reminder letter was sent to both groups if necessary. The main primary outcome was the FIT completion rate within 30, 60, and 126 days from FIT kit pick up (intention-to-treat analysis). A telephone survey assessed the acceptability and appropriateness of the intervention. The cost-effectiveness of adding an SMS text message reminder to FIT completion was also performed., Results: The intervention group had higher FIT completion rates than the control group at 30 (64.2% vs 53.7%; P<.001), 60 (78.6% vs 72.0%; P<.001), and 126 (82.6% vs 77.7%; P<.001) days. Participation rates were higher in the intervention arm independent of sex, age, socioeconomic level, and previous screening behavior. A total of 339 (89.2%) interviewees considered it important and useful to receive SMS text message reminders for FIT completion and 355 (93.4%) preferred SMS text messages to postal letters. We observed a reduction of US $2.4 per participant gained in the intervention arm for invitation costs compared to the control arm., Conclusions: Adding an SMS text message reminder to the standard procedure significantly increased FIT kit return rates and was a cost-effective strategy. SMS text messages also proved to be an acceptable and appropriate communication channel for cancer screening programs., Trial Registration: ClinicalTrials.gov NCT04343950; https://www.clinicaltrials.gov/study/NCT04343950., International Registered Report Identifier (irrid): RR2-10.1371/journal.pone.0245806., (©Nuria Vives, Noemie Travier, Albert Farre, Gemma Binefa, Carmen Vidal, Maria Jose Pérez Lacasta, Gemma Ibáñez-Sanz, Ena Pery Niño de Guzmán, Jon Aritz Panera, Montse Garcia, M-TICS Research Group. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 31.07.2024.)
- Published
- 2024
- Full Text
- View/download PDF
7. Comparison between 16S rRNA and shotgun sequencing in colorectal cancer, advanced colorectal lesions, and healthy human gut microbiota.
- Author
-
Bars-Cortina D, Ramon E, Rius-Sansalvador B, Guinó E, Garcia-Serrano A, Mach N, Khannous-Lleiffe O, Saus E, Gabaldón T, Ibáñez-Sanz G, Rodríguez-Alonso L, Mata A, García-Rodríguez A, Obón-Santacana M, and Moreno V
- Subjects
- Humans, Feces microbiology, Metagenomics methods, Bacteria genetics, Bacteria classification, Sequence Analysis, DNA methods, Male, Metagenome, Female, Colorectal Neoplasms microbiology, Colorectal Neoplasms genetics, RNA, Ribosomal, 16S genetics, Gastrointestinal Microbiome genetics
- Abstract
Background: Gut dysbiosis has been associated with colorectal cancer (CRC), the third most prevalent cancer in the world. This study compares microbiota taxonomic and abundance results obtained by 16S rRNA gene sequencing (16S) and whole shotgun metagenomic sequencing to investigate their reliability for bacteria profiling. The experimental design included 156 human stool samples from healthy controls, advanced (high-risk) colorectal lesion patients (HRL), and CRC cases, with each sample sequenced using both 16S and shotgun methods. We thoroughly compared both sequencing technologies at the species, genus, and family annotation levels, the abundance differences in these taxa, sparsity, alpha and beta diversities, ability to train prediction models, and the similarity of the microbial signature derived from these models., Results: As expected, the results showed that 16S detects only part of the gut microbiota community revealed by shotgun, although some genera were only profiled by 16S. The 16S abundance data was sparser and exhibited lower alpha diversity. In lower taxonomic ranks, shotgun and 16S highly differed, partially due to a disagreement in reference databases. When considering only shared taxa, the abundance was positively correlated between the two strategies. We also found a moderate correlation between the shotgun and 16S alpha-diversity measures, as well as their PCoAs. Regarding the machine learning models, only some of the shotgun models showed some degree of predictive power in an independent test set, but we could not demonstrate a clear superiority of one technology over the other. Microbial signatures from both sequencing techniques revealed taxa previously associated with CRC development, e.g., Parvimonas micra., Conclusions: Shotgun and 16S sequencing provide two different lenses to examine microbial communities. While we have demonstrated that they can unravel common patterns (including microbial signatures), shotgun often gives a more detailed snapshot than 16S, both in depth and breadth. Instead, 16S will tend to show only part of the picture, giving greater weight to dominant bacteria in a sample. Therefore, we recommend choosing one or another sequencing technique before launching a study. Specifically, shotgun sequencing is preferred for stool microbiome samples and in-depth analyses, while 16S is more suitable for tissue samples and studies with targeted aims., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
8. Performance of a Shotgun Prediction Model for Colorectal Cancer When Using 16S rRNA Sequencing Data.
- Author
-
Ramon E, Obón-Santacana M, Khannous-Lleiffe O, Saus E, Gabaldón T, Guinó E, Bars-Cortina D, Ibáñez-Sanz G, Rodríguez-Alonso L, Mata A, García-Rodríguez A, and Moreno V
- Subjects
- Humans, RNA, Ribosomal, 16S genetics, Algorithms, Health Personnel, Gastrointestinal Microbiome genetics, Colorectal Neoplasms genetics
- Abstract
Colorectal cancer (CRC), the third most common cancer globally, has shown links to disturbed gut microbiota. While significant efforts have been made to establish a microbial signature indicative of CRC using shotgun metagenomic sequencing, the challenge lies in validating this signature with 16S ribosomal RNA (16S) gene sequencing. The primary obstacle is reconciling the differing outputs of these two methodologies, which often lead to divergent statistical models and conclusions. In this study, we introduce an algorithm designed to bridge this gap by mapping shotgun-derived taxa to their 16S counterparts. This mapping enables us to assess the predictive performance of a shotgun-based microbiome signature using 16S data. Our results demonstrate a reduction in performance when applying the 16S-mapped taxa in the shotgun prediction model, though it retains statistical significance. This suggests that while an exact match between shotgun and 16S data may not yet be feasible, our approach provides a viable method for comparative analysis and validation in the context of CRC-associated microbiome research.
- Published
- 2024
- Full Text
- View/download PDF
9. Meta-Analysis and Validation of a Colorectal Cancer Risk Prediction Model Using Deep Sequenced Fecal Metagenomes.
- Author
-
Obón-Santacana M, Mas-Lloret J, Bars-Cortina D, Criado-Mesas L, Carreras-Torres R, Díez-Villanueva A, Moratalla-Navarro F, Guinó E, Ibáñez-Sanz G, Rodríguez-Alonso L, Mulet-Margalef N, Mata A, García-Rodríguez A, Duell EJ, Pimenoff VN, and Moreno V
- Abstract
The gut microbiome is a potential modifiable risk factor for colorectal cancer (CRC). We re-analyzed all eight previously published stool sequencing data and conducted an MWAS meta-analysis. We used cross-validated LASSO predictive models to identify a microbiome signature for predicting the risk of CRC and precancerous lesions. These models were validated in a new study, Colorectal Cancer Screening (COLSCREEN), including 156 participants that were recruited in a CRC screening context. The MWAS meta-analysis identified 95 bacterial species that were statistically significantly associated with CRC (FDR < 0.05). The LASSO CRC predictive model obtained an area under the receiver operating characteristic curve (aROC) of 0.81 (95%CI: 0.78−0.83) and the validation in the COLSCREEN dataset was 0.75 (95%CI: 0.66−0.84). This model selected a total of 32 species. The aROC of this CRC-trained model to predict precancerous lesions was 0.52 (95%CI: 0.41−0.63). We have identified a signature of 32 bacterial species that have a good predictive accuracy to identify CRC but not precancerous lesions, suggesting that the identified microbes that were enriched or depleted in CRC are merely a consequence of the tumor. Further studies should focus on CRC as well as precancerous lesions with the intent to implement a microbiome signature in CRC screening programs.
- Published
- 2022
- Full Text
- View/download PDF
10. Post-polypectomy colonoscopy surveillance: Can we improve the diagnostic yield?
- Author
-
Ibáñez-Sanz G, Sanz-Pamplona R, and Garcia M
- Subjects
- Colonoscopy, Humans, Pandemics, COVID-19, Colonic Polyps diagnosis, Colonic Polyps epidemiology, Colonic Polyps surgery, Colorectal Neoplasms diagnosis, Colorectal Neoplasms epidemiology, Colorectal Neoplasms surgery
- Abstract
Although adenomas and serrated polyps are the preneoplastic lesions of colorectal cancer, only few of them will eventually progress to cancer. This review provides a comprehensive overview of the present and future of post-polypectomy colonoscopy surveillance. Post-polypectomy surveillance guidelines have recently been updated and all share the aim towards more selective and less frequent surveillance. We have examined these current guidelines and compared the recommendations of each of them. To improve the diagnostic yield of post-polypectomy surveillance it is important to find predictors of metachronous polyps that better identify high-risk individuals of developing advanced neoplasia. For this reason, we have also conducted a literature review of the molecular biomarkers of metachronous advanced colorectal polyps. Finally, we have discussed future directions of post-polypectomy surveillance and identified possible strategies to improve the use of endoscopic resources with the COVID-19 pandemic., (Copyright © 2021 Elsevier España, S.L.U. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
11. Transcriptome-Wide Association Study for Inflammatory Bowel Disease Reveals Novel Candidate Susceptibility Genes in Specific Colon Subsites and Tissue Categories.
- Author
-
Díez-Obrero V, Moratalla-Navarro F, Ibáñez-Sanz G, Guardiola J, Rodríguez-Moranta F, Obón-Santacana M, Díez-Villanueva A, Dampier CH, Devall M, Carreras-Torres R, Casey G, and Moreno V
- Subjects
- Colon metabolism, Genetic Predisposition to Disease, Humans, Polymorphism, Single Nucleotide, Transcriptome, Genome-Wide Association Study methods, Inflammatory Bowel Diseases genetics, Inflammatory Bowel Diseases metabolism
- Abstract
Background and Aims: Genome-wide association studies [GWAS] for inflammatory bowel disease [IBD] have identified 240 risk variants. However, the benefit of understanding the genetic architecture of IBD remains to be exploited. Transcriptome-wide association studies [TWAS] associate gene expression with genetic susceptibility to disease, providing functional insight into risk loci. In this study, we integrate relevant datasets for IBD and perform a TWAS to nominate novel genes implicated in IBD genetic susceptibility., Methods: We applied elastic net regression to generate gene expression prediction models for the University of Barcelona and University of Virginia RNA sequencing project [BarcUVa-Seq] and correlated expression and disease association research [CEDAR] datasets. Together with Genotype-Tissue Expression project [GTEx] data, and GWAS results from about 60 000 individuals, we employed Summary-PrediXcan and Summary-MultiXcan for single and joint analyses of TWAS results, respectively., Results: BarcUVa-Seq TWAS revealed 39 novel genes whose expression in the colon is associated with IBD genetic susceptibility. They included expression markers for specific colon cell types. TWAS meta-analysis including all tissues/cell types provided 186 novel candidate susceptibility genes. Additionally, we identified 78 novel susceptibility genes whose expression is associated with IBD exclusively in immune (N = 19), epithelial (N = 25), mesenchymal (N = 22) and neural (N = 12) tissue categories. Associated genes were involved in relevant molecular pathways, including pathways related to known IBD therapeutics, such as tumour necrosis factor signalling., Conclusion: These findings provide insight into tissue-specific molecular processes underlying IBD genetic susceptibility. Associated genes could be candidate targets for new therapeutics and should be prioritized in functional studies., (© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
12. Diagnostic Performance of a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program According to Ambient Temperature and Humidity.
- Author
-
Ibáñez-Sanz G, Milà N, Vives N, Vidal C, Binefa G, Rocamora J, Atencia C, Moreno V, Sanz-Pamplona R, Garcia M, and On Behalf Of The Msic-Sc Research Group
- Abstract
Exposure of the fecal immunochemical test (FIT) to different ambient temperatures and humidity is unavoidable in population-based screening programs in Southern European countries, and it could lead to a decrease in target colorectal lesions. The objective was to evaluate the effect of ambient temperature and humidity on the FIT sensitivity in a population-based screening program for colorectal cancer (CRC) using an ecological design. The retrospective cohort included individuals aged 50−69 years who participated in CRC screening (Barcelona) from 2010−2015, and were followed until 2017 to identify interval CRCs. The positivity rate, and detection rates for advanced polyps and CRC were compared according to ambient temperature, humidity, and quarters of the year. A positive FIT was defined as the detection of ≥20 μg Hb/g in feces. The monthly ambient temperature and humidity were recorded on the day that the FIT was performed. In total, 92,273 FIT results from 53,860 participants were analyzed. The FIT positivity rate was lower at >24 °C than at ≤24 °C (p = 0.005) but was not affected by humidity. The temperature’s impact on positivity did not lead to a decrease in the FIT detection rate for advanced neoplasia or the interval cancer detection rate in a program where the samples were refrigerated until the analysis and screening invitations were discontinued in July and August.
- Published
- 2022
- Full Text
- View/download PDF
13. Polygenic risk score across distinct colorectal cancer screening outcomes: from premalignant polyps to colorectal cancer.
- Author
-
Obón-Santacana M, Díez-Villanueva A, Alonso MH, Ibáñez-Sanz G, Guinó E, López A, Rodríguez-Alonso L, Mata A, García-Rodríguez A, Palomo AG, Molina AJ, Garcia M, Binefa G, Martín V, and Moreno V
- Subjects
- Colonoscopy, Humans, Occult Blood, Risk Factors, Colorectal Neoplasms diagnosis, Colorectal Neoplasms epidemiology, Colorectal Neoplasms genetics, Early Detection of Cancer
- Abstract
Background: Different risk-based colorectal cancer (CRC) screening strategies, such as the use of polygenic risk scores (PRS), have been evaluated to improve effectiveness of these programs. However, few studies have previously assessed its usefulness in a fecal immunochemical test (FIT)-based screening study., Methods: A PRS of 133 single nucleotide polymorphisms was assessed for 3619 participants: population controls, screening controls, low-risk lesions (LRL), intermediate-risk (IRL), high-risk (HRL), CRC screening program cases, and clinically diagnosed CRC cases. The PRS was compared between the subset of cases (n = 648; IRL+HRL+CRC) and controls (n = 956; controls+LRL) recruited within a FIT-based screening program. Positive predictive values (PPV), negative predictive values (NPV), and the area under the receiver operating characteristic curve (aROC) were estimated using cross-validation., Results: The overall PRS range was 110-156. PRS values increased along the CRC tumorigenesis pathway (Mann-Kendall P value 0.007). Within the screening subset, the PRS ranged 110-151 and was associated with higher risk-lesions and CRC risk (OR
D10vsD1 1.92, 95% CI 1.22-3.03). The cross-validated aROC of the PRS for cases and controls was 0.56 (95% CI 0.53-0.59). Discrimination was equal when restricted to positive FIT (aROC 0.56), but lower among negative FIT (aROC 0.55). The overall PPV among positive FIT was 0.48. PPV were dependent on the number of risk alleles for positive FIT (PPVp10-p90 0.48-0.57)., Conclusions: PRS plays an important role along the CRC tumorigenesis pathway; however, in practice, its utility to stratify the general population or as a second test after a FIT positive result is still doubtful. Currently, PRS is not able to safely stratify the general population since the improvement on PPV values is scarce., (© 2021. The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
14. Positive impact of a faecal-based screening programme on colorectal cancer mortality risk.
- Author
-
Ibáñez-Sanz G, Milà N, Vidal C, Rocamora J, Moreno V, Sanz-Pamplona R, and Garcia M
- Subjects
- Aged, Colorectal Neoplasms diagnosis, Early Detection of Cancer methods, Female, Humans, Male, Middle Aged, Neoplasm Staging, Patient Acceptance of Health Care, Retrospective Studies, Risk Assessment statistics & numerical data, Spain, Colorectal Neoplasms mortality, Early Detection of Cancer statistics & numerical data, Occult Blood
- Abstract
Introduction: The effectiveness of colorectal cancer (CRC) screening programs is directly related to participation and the number of interval CRCs. The objective was to analyse specific-mortality in a cohort of individuals invited to a CRC screening program according to type of CRC diagnosis (screen-detected cancers, interval cancers, and cancers among the non-uptake group)., Material and Methods: Retrospective cohort that included invitees aged 50-69 years of a CRC screening program (target population of 85,000 people) in Catalonia (Spain) from 2000-2015 with mortality follow-up until 2020. A screen-detected CRC was a cancer diagnosed after a positive faecal occult blood test (guaiac or immunochemical); an interval cancer was a cancer diagnosed after a negative test result and before the next invitation to the program (≤24 months); a non-uptake cancer was a cancer in subjects who declined screening., Results: A total of 624 people were diagnosed with CRC (n = 265 screen-detected, n = 103 interval cancers, n = 256 non-uptake). In the multivariate analysis, we observed a 74% increase in mortality rate in the group with interval CRC compared to screen-detected CRC adjusted for age, sex, location and stage (HR: 1.74%, 95% CI:1.08-2.82, P = 0.02). These differences were found even when we restricted for advanced-cancers participants. In the stratified analysis for type of faecal occult blood test, a lower mortality rate was only observed among FIT screen-detected CRCs., Conclusion: CRC screening with the FIT was associated with a significant reduction in CRC mortality., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
15. Future Prospects of Colorectal Cancer Screening: Characterizing Interval Cancers.
- Author
-
Ibáñez-Sanz G, Sanz-Pamplona R, Garcia M, and On Behalf Of The Msic-Sc Research Group
- Abstract
Tumors that are not detected by screening tests are known as interval cancers and are diagnosed clinically after a negative result in the screening episode but before the next screening invitation. Clinical characteristics associated with interval colorectal cancers have been studied, but few molecular data are available that describe interval colorectal cancers. A better understanding of the clinical and biological characteristics associated with interval colorectal cancer may provide new insights into how to prevent this disease more effectively. This review aimed to summarize the current literature concerning interval colorectal cancer and its epidemiological, clinical, and molecular features., Competing Interests: The authors declare no conflict of interest.
- Published
- 2021
- Full Text
- View/download PDF
16. Text messaging as a tool to improve cancer screening programs (M-TICS Study): A randomized controlled trial protocol.
- Author
-
Vives N, Farre A, Ibáñez-Sanz G, Vidal C, Binefa G, Milà N, Pérez-Lacasta MJ, Travier N, Benito L, Espinàs JA, Bagaria G, and Garcia M
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Outcome Assessment, Health Care, Breast Neoplasms diagnosis, Colorectal Neoplasms diagnosis, Mass Screening methods, Text Messaging
- Abstract
Background: Short message service (SMS) based interventions are widely used in healthcare and have shown promising results to improve cancer screening programs. However, more research is still needed to implement SMS in the screening process. We present a study protocol to assess the impact on health and economics of three targeted SMS-based interventions in population-based cancer screening programs., Methods/design: The M-TICs study is a randomized controlled trial with a formal process evaluation. Participants aged 50-69 years identified as eligible from the colorectal cancer (CRC) and breast cancer (BC) screening program of the Catalan Institute of Oncology (Catalonia, Spain) will be randomly assigned to receive standard invitation procedure (control group) or SMS-based intervention to promote participation. Two interventions will be conducted in the CRC screening program: 1) Screening invitation reminder: Those who do not participate in the CRC screening within 6 weeks of invite will receive a reminder (SMS or letter); 2) Reminder to complete and return fecal immunochemical test (FIT) kit: SMS reminder versus no intervention to individuals who have picked up a FIT kit at the pharmacy and they have not returned it after 14 days. The third intervention will be performed in the BC screening program. Women who had been screened previously will receive an SMS invitation or a letter invitation to participate in the screening. As a primary objective we will assess the impact on participation for each intervention. The secondary objectives will be to analyze the cost-effectiveness of the interventions and to assess participants' perceptions., Expected Results: The results from this randomized controlled trial will provide important empirical evidence for the use of mobile phone technology as a tool for improving population-based cancer screening programs. These results may influence the cancer screening invitation procedure in future routine practice., Trial Registration: Registry: NCT04343950 (04/09/2020); clinicaltrials.gov., Competing Interests: Authors declare funding from ISCIII; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.
- Published
- 2021
- Full Text
- View/download PDF
17. Proton-pump inhibitors are associated with a high false-positivity rate in faecal immunochemical testing.
- Author
-
Ibáñez-Sanz G, Milà N, de la Peña-Negro LC, Garcia M, Vidal C, Rodríguez-Alonso L, Binefa G, Rodríguez-Moranta F, and Moreno V
- Subjects
- Aged, Colonoscopy, False Positive Reactions, Female, Follow-Up Studies, Humans, Logistic Models, Male, Middle Aged, Odds Ratio, Retrospective Studies, Unnecessary Procedures, Adenoma diagnosis, Carcinoma diagnosis, Colorectal Neoplasms diagnosis, Early Detection of Cancer methods, Occult Blood, Proton Pump Inhibitors
- Abstract
Background: False-positivity rates in faecal immunochemical test (FIT) can be affected by drug exposure. We aimed to assess the association between proton pump inhibitors (PPI) consumption and false positive (FP) results in a colorectal cancer (CRC) screening programme using electronic prescription records., Methods: A retrospective cohort study within a population-based screening program for CRC from 2010 to 2016 was performed. Participants with a conclusive FIT result and with prescription electronic data were included. An FP result was defined as having a positive FIT (≥ 20 µg haemoglobin/g faeces) and a follow-up colonoscopy without intermediate or high-risk lesions or CRC. Screening data were anonymously linked to the public data analysis program for health research and innovation (PADRIS) database that recorded patient diseases history and reimbursed medication. PPI exposure was defined as having retrieved at least one dispensation of PPI three months prior to the FIT., Results: A total of 89,199 tests (of 46,783 participants) were analysed, 4824 (5.4%) tested positive and the proportion of FP was 53.5%. Overall, 17,544 participants (19.7%) were PPI users prior to FIT performance. PPI exposure increased the probability of obtaining an FP FIT result from 50.4 to 63.3% (adjusted OR 1.39; 95% CI 1.18-1.65). Nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, antibiotics, and laxatives were also associated with an FP result. The effect of PPI was independent and showed a synergistic interaction with nonsteroidal anti-inflammatory drugs., Conclusion: PPIs increase FIT positivity at the expense of FP results. The recommendation to avoid their use before FIT performance could reduce up to 3% of colonoscopies and 9% of FP results.
- Published
- 2021
- Full Text
- View/download PDF
18. Genetic Effects on Transcriptome Profiles in Colon Epithelium Provide Functional Insights for Genetic Risk Loci.
- Author
-
Díez-Obrero V, Dampier CH, Moratalla-Navarro F, Devall M, Plummer SJ, Díez-Villanueva A, Peters U, Bien S, Huyghe JR, Kundaje A, Ibáñez-Sanz G, Guinó E, Obón-Santacana M, Carreras-Torres R, Casey G, and Moreno V
- Subjects
- Female, Humans, Male, Middle Aged, Transcriptome, Alternative Splicing genetics, Colon metabolism, Epithelium metabolism, Polymorphism, Single Nucleotide genetics, Quantitative Trait Loci genetics
- Abstract
Background & Aims: The association of genetic variation with tissue-specific gene expression and alternative splicing guides functional characterization of complex trait-associated loci and may suggest novel genes implicated in disease. Here, our aims were as follows: (1) to generate reference profiles of colon mucosa gene expression and alternative splicing and compare them across colon subsites (ascending, transverse, and descending), (2) to identify expression and splicing quantitative trait loci (QTLs), (3) to find traits for which identified QTLs contribute to single-nucleotide polymorphism (SNP)-based heritability, (4) to propose candidate effector genes, and (5) to provide a web-based visualization resource., Methods: We collected colonic mucosal biopsy specimens from 485 healthy adults and performed bulk RNA sequencing. We performed genome-wide SNP genotyping from blood leukocytes. Statistical approaches and bioinformatics software were used for QTL identification and downstream analyses., Results: We provided a complete quantification of gene expression and alternative splicing across colon subsites and described their differences. We identified thousands of expression and splicing QTLs and defined their enrichment at genome-wide regulatory regions. We found that part of the SNP-based heritability of diseases affecting colon tissue, such as colorectal cancer and inflammatory bowel disease, but also of diseases affecting other tissues, such as psychiatric conditions, can be explained by the identified QTLs. We provided candidate effector genes for multiple phenotypes. Finally, we provided the Colon Transcriptome Explorer web application., Conclusions: We provide a large characterization of gene expression and splicing across colon subsites. Our findings provide greater etiologic insight into complex traits and diseases influenced by transcriptomic changes in colon tissue., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
19. Identifying environmental risk factors for inflammatory bowel diseases: a Mendelian randomization study.
- Author
-
Carreras-Torres R, Ibáñez-Sanz G, Obón-Santacana M, Duell EJ, and Moreno V
- Subjects
- Adult, Body Mass Index, Colitis, Ulcerative epidemiology, Colitis, Ulcerative pathology, Crohn Disease epidemiology, Crohn Disease pathology, Female, Genome-Wide Association Study, Humans, Male, Mendelian Randomization Analysis, Obesity epidemiology, Obesity genetics, Obesity pathology, Risk Factors, Smoking epidemiology, Smoking genetics, Smoking pathology, Colitis, Ulcerative genetics, Crohn Disease genetics, Gene-Environment Interaction
- Abstract
Several studies have examined environmental factors and inflammatory bowel diseases (IBD) using traditional approaches; however, provided results are still conflicting. Our aim was to determine whether lifestyle and nutrient exposures, related to IBD in observational meta-analyses, influence IBD risk using a Mendelian randomization (MR) approach. A two-sample MR approach was applied on summary-level genome-wide association results. Genetic variants strongly associated with measures of tobacco smoking, obesity and fat distribution, physical activity, and blood levels of vitamins and fatty acids were evaluated on genetic data from international IBD consortia including a total of 25,042 IBD cases (12,194 cases of Crohn's disease (CD) and 12,366 cases of ulcerative colitis (UC)) and 34,915 controls. Our results indicated that, among lifestyle exposures, being a smoker was positively associated with CD (OR 1.13, P = 0.02), but it was not associated with UC risk (OR 0.99, P = 0.88). Body-mass index (BMI) and body fat percentage were positively associated with CD (OR 1.11, P = 0.02, per standard deviation (SD) of 4.6 kg/m
2 ; and OR 1.50, P = 3 × 10-10 , per SD of 6.6%; respectively); while for UC, BMI was inversely associated (OR 0.85, P = 5 × 10-5 ; per SD) and body fat percentage showed a OR of 1.11 (P = 0.11; per SD). Additionally, among nutrient exposures, omega-3 fatty acids levels were inversely associated with CD (OR 0.67, P = 2 × 10-6 ). Our MR results did not support a protective effect for being a smoker on UC risk; however, they are compatible with a risk effect for higher body fat proportion and a protective role for higher levels of omega-3 fatty acids on CD etiology.- Published
- 2020
- Full Text
- View/download PDF
20. Chondroitin Sulphate and Glucosamine Use Depend on Nonsteroidal Anti-inflammatory Drug Use to Modify the Risk for Colorectal Cancer.
- Author
-
Ibáñez-Sanz G, Guinó E, Morros R, Quijada-Manuitt MÁ, de la Peña-Negro LC, and Moreno V
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Antineoplastic Combined Chemotherapy Protocols pharmacology, Case-Control Studies, Chondroitin Sulfates pharmacology, Female, Glucosamine pharmacology, Humans, Male, Middle Aged, Prevalence, Risk Factors, Young Adult, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chondroitin Sulfates therapeutic use, Colorectal Neoplasms drug therapy, Glucosamine therapeutic use
- Abstract
Background: A safe and effective colorectal cancer chemoprevention agent remains to be discovered. There is little evidence regarding the protective effect of chondroitin sulphate and glucosamine on colorectal cancer. We aimed to assess the association between colorectal cancer risk and the use of chondroitin sulphate and glucosamine using a large cohort with dispensed data., Methods: We performed a population-based case-control study in Catalonia using primary care reimbursed medication records (SIDIAP database). The study included 25,811 cases with an incident diagnosis of colorectal cancer and 129,117 matched controls between 2010 and 2015., Results: The prevalence of ever use was 9.0% ( n = 13,878) for chondroitin sulphate, 7.3% ( n = 11,374) for glucosamine, and 35% for regular use of nonsteroidal anti-inflammatory drugs (NSAID; n = 45,774). A decreased risk of colorectal cancer was observed among chondroitin sulphate use [OR: 0.96; 95% confidence interval (CI), 0.91-1.01], glucosamine use (OR: 0.92; 95% CI, 0.87-0.97), and concurrent use of chondroitin sulphate and glucosamine (OR: 0.83; 95% CI, 0.70-0.98). Especially for glucosamine, there was a dose-response association regarding duration and cumulative dose. The analysis stratified by simultaneous use with other NSAIDs showed that these drugs used without other NSAIDs do not reduce risk (OR: 1.06; 95% CI, 0.74-1.51). However, they may have a synergistic protective effect when used with other NSAIDs (OR: 0.80; 95% CI, 0.72-0.88)., Conclusions: This study does not provide strong support for an independent protective association of chondroitin sulphate or glucosamine on colorectal cancer risk in our population. However, these drugs may have a synergistic beneficial effect among NSAID users., Impact: Chondroitin sulphate or glucosamine may contribute to the protective effect of NSAID use in colorectal cancer., (©2020 American Association for Cancer Research.)
- Published
- 2020
- Full Text
- View/download PDF
21. Gut microbiome diversity detected by high-coverage 16S and shotgun sequencing of paired stool and colon sample.
- Author
-
Mas-Lloret J, Obón-Santacana M, Ibáñez-Sanz G, Guinó E, Pato ML, Rodriguez-Moranta F, Mata A, García-Rodríguez A, Moreno V, and Pimenoff VN
- Subjects
- Cross-Sectional Studies, Female, High-Throughput Nucleotide Sequencing, Humans, Male, Metagenomics, Colon, Feces, Gastrointestinal Microbiome genetics, RNA, Ribosomal, 16S genetics
- Abstract
The gut microbiome has a fundamental role in human health and disease. However, studying the complex structure and function of the gut microbiome using next generation sequencing is challenging and prone to reproducibility problems. Here, we obtained cross-sectional colon biopsies and faecal samples from nine participants in our COLSCREEN study and sequenced them in high coverage using Illumina pair-end shotgun (for faecal samples) and IonTorrent 16S (for paired feces and colon biopsies) technologies. The metagenomes consisted of between 47 and 92 million reads per sample and the targeted sequencing covered more than 300 k reads per sample across seven hypervariable regions of the 16S gene. Our data is freely available and coupled with code for the presented metagenomic analysis using up-to-date bioinformatics algorithms. These results will add up to the informed insights into designing comprehensive microbiome analysis and also provide data for further testing for unambiguous gut microbiome analysis.
- Published
- 2020
- Full Text
- View/download PDF
22. Risk of colorectal cancer in users of bisphosphonates: analysis of population-based electronic health records.
- Author
-
Ibáñez-Sanz G, Guinó E, Pontes C, Morros R, de la Peña-Negro LC, Quijada-Manuitt MÁ, and Moreno V
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Bone Density Conservation Agents administration & dosage, Case-Control Studies, Chemoprevention, Diphosphonates administration & dosage, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Population Surveillance, Young Adult, Bone Density Conservation Agents therapeutic use, Colorectal Neoplasms epidemiology, Colorectal Neoplasms prevention & control, Diphosphonates therapeutic use, Electronic Health Records statistics & numerical data
- Abstract
The use of bisphosphonates has been associated with a decrease in the risk of colorectal cancer (CRC) in observational studies, but with controversial results and difficult to interpret because of routine concomitant use of calcium and vitamin D. We aimed to assess the association between CRC risk and outpatient exposure to antiosteoporotic drugs using a large cohort with prescription data in Catalonia. A case-control study was performed using the Information System for Development of Primary Care Research (SIDIAP) which is a primary care medical record database that has linked data on reimbursed medication. The study included 25,836 cases with an incident diagnosis of CRC between 2010 and 2015 and 129,117 matched controls by age (± 5 years), sex and healthcare region. A multivariable model was built adjusting for known risk factors and comorbidities that were significantly associated to CRC in the dataset, and a propensity score for bisphosphonates. Tests for interaction for multiple drug use and stratified analysis for tumour location were prospectively planned. Overall 18,230 individuals (11.5%) were users of bisphosphonates. A significant but modest protective effect on CRC was observed for bisphosphonates (OR 0.95, 95% CI 0.91-0.99), that was no longer significant when adjusted for calcium and vitamin D (OR 0.98, 95% CI 0.93-1.03). Bisphosphonates, however, showed a dose-response effect with duration of use even when adjusted for calcium and vitamin D (OR for use > 40 months: 0.90, 95% CI 0.81-1.00, P value for trend: 0.018). The use of bisphosphonates was associated with a modest decrease in the risk of CRC, but this effect was essentially explained by concomitant use of calcium or vitamin D. The observed protective effect was stronger for long durations of use, which deserves further study.
- Published
- 2020
- Full Text
- View/download PDF
23. False-Positive Results in a Population-Based Colorectal Screening Program: Cumulative Risk from 2000 to 2017 with Biennial Screening.
- Author
-
Ibáñez-Sanz G, Garcia M, Milà N, Hubbard RA, Vidal C, Binefa G, Benito L, and Moreno V
- Subjects
- Aged, Cohort Studies, False Positive Reactions, Female, History, 21st Century, Humans, Male, Middle Aged, Retrospective Studies, Colorectal Neoplasms diagnosis, Early Detection of Cancer methods
- Abstract
Background: The aim of this study was to estimate the cumulative risk of a false-positive (FP) result in a fecal occult blood test (FOBT) through 7 screening rounds and to identify its associated factors in a population-based colorectal cancer screening program., Methods: Retrospective cohort study, which included participants ages 50 to 69 years of a colorectal cancer screening program in Catalonia, Spain. During this period, 2 FOBTs were used (guaiac and immunochemical). A discrete-time survival model was performed to identify risk factors of receiving a positive FOBT with no high-risk adenoma or colorectal cancer in the follow-up colonoscopy. We estimated the probability of having at least 1 FP over 7 screening rounds., Results: During the period of 2000 to 2017, the cumulative FP risk was 16.3% (IC
95% : 14.6%-18.3%), adjusted by age, sex, and type of test. The median number of screens was 2. Participants who began screening at age 50 years had a 7.3% [95% confidence interval (CI), 6.35-8.51] and a 12.4% (95% CI, 11.00-13.94) probability of an FP with 4 screening rounds of guaiac-based test and immunochemical test, respectively. Age, the fecal immunochemical test, first screening, and number of personal screens were factors associated with an FP result among screenees., Conclusions: The cumulative risk of an FP in colorectal screening using FOBT seems acceptable as the colonoscopy, with its high accuracy, lengthens the time until additional colorectal screening is required, while complication rates remain low., Impact: It is useful to determine the cumulative FP risk in cancer screening for both advising individuals and for health resources planning., (©2019 American Association for Cancer Research.)- Published
- 2019
- Full Text
- View/download PDF
24. Statin use and the risk of colorectal cancer in a population-based electronic health records study.
- Author
-
Ibáñez-Sanz G, Guinó E, Pontes C, Quijada-Manuitt MÁ, de la Peña-Negro LC, Aragón M, Domínguez M, Rodríguez-Alonso L, Blasco A, García-Rodríguez A, Morros R, and Moreno V
- Subjects
- Administrative Claims, Healthcare, Adult, Aged, Aged, 80 and over, Case-Control Studies, Electronic Health Records, Female, Humans, Male, Middle Aged, Spain epidemiology, Young Adult, Colorectal Neoplasms epidemiology, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage
- Abstract
There is extensive debate regarding the protective effect of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) on colorectal cancer (CRC). We aimed to assess the association between CRC risk and exposure to statins using a large cohort with prescription data. We carried out a case-control study in Catalonia using the System for Development of Primary Care Research (SIDIAP) database that recorded patient diseases history and linked data on reimbursed medication. The study included 25 811 cases with an incident diagnosis of CRC between 2010 and 2015 and 129 117 frequency-matched controls. Subjects were classified as exposed to statins if they had ever been dispensed statins. Analysis considering mean daily defined dose, cumulative duration and type of statin were performed. Overall, 66 372 subjects (43%) were exposed to statins. There was no significant decrease of CRC risk associated to any statin exposure (OR = 0.98; 95% CI: 0.95-1.01). Only in the stratified analysis by location a reduction of risk for rectal cancer was observed associated to statin exposure (OR = 0.87; 95% CI: 0.81-0.92). This study does not support an overall protective effect of statins in CRC, but a protective association with rectal cancer merits further research.
- Published
- 2019
- Full Text
- View/download PDF
25. Mendelian randomization analysis rules out disylipidaemia as colorectal cancer cause.
- Author
-
Ibáñez-Sanz G, Díez-Villanueva A, Riera-Ponsati M, Fernández-Villa T, Fernández Navarro P, Bustamante M, Llorca J, Amiano P, Ascunce N, Fernández-Tardón G, Salcedo Bellido I, Salas D, Capelo Álvarez R, Crous-Bou M, Ortega-Valín L, Pérez-Gómez B, Castaño-Vinyals G, Palazuelos C, Altzibar JM, Ardanaz E, Tardón A, Jiménez Moleón JJ, Olmos Juste V, Aragonés N, Pollán M, Kogevinas M, and Moreno V
- Subjects
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Female, Follow-Up Studies, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Incidence, Male, Middle Aged, Prognosis, Risk Factors, Spain epidemiology, Young Adult, Colorectal Neoplasms epidemiology, Dyslipidemias physiopathology, Lipids analysis, Mendelian Randomization Analysis, Polymorphism, Single Nucleotide
- Abstract
Dyslipidemia and statin use have been associated with colorectal cancer (CRC), but prospective studies have shown mixed results. We aimed to determine whether dyslipidemia is causally linked to CRC risk using a Mendelian randomization approach and to explore the association of statins with CRC. A case-control study was performed including 1336 CRC cases and 2744 controls (MCC-Spain). Subjects were administered an epidemiological questionnaire and were genotyped with an array which included polymorphisms associated with blood lipids levels, selected to avoid pleiotropy. Four genetic lipid scores specific for triglycerides (TG), high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), or total cholesterol (TC) were created as the count of risk alleles. The genetic lipid scores were not associated with CRC. The ORs per 10 risk alleles, were for TG 0.91 (95%CI: 0.72-1.16, p = 0.44), for HDL 1.14 (95%CI: 0.95-1.37, p = 0.16), for LDL 0.97 (95%CI: 0.81-1.16, p = 0.73), and for TC 0.98 (95%CI: 0.84-1.17, p = 0.88). The LDL and TC genetic risk scores were associated with statin use, but not the HDL or TG. Statin use, overall, was a non-significant protective factor for CRC (OR 0.84; 95%CI: 0.70-1.01, p = 0.060), but lipophilic statins were associated with a CRC risk reduction (OR 0.78; 95%CI 0.66-0.96, p = 0.018). Using the Mendelian randomization approach, our study does not support the hypothesis that lipid levels are associated with the risk of CRC. This study does not rule out, however, a possible protective effect of statins in CRC by a mechanism unrelated to lipid levels.
- Published
- 2019
- Full Text
- View/download PDF
26. Proton pump inhibitors reduce the accuracy of faecal immunochemical test for detecting advanced colorectal neoplasia in symptomatic patients.
- Author
-
Rodriguez-Alonso L, Rodriguez-Moranta F, Arajol C, Gilabert P, Serra K, Martin A, Ibáñez-Sanz G, Moreno V, and Guardiola J
- Subjects
- Adenoma diagnosis, Colonoscopy methods, Early Detection of Cancer methods, Female, Humans, Male, Middle Aged, Prospective Studies, Sensitivity and Specificity, Colorectal Neoplasms diagnosis, Feces chemistry, Proton Pump Inhibitors chemistry
- Abstract
Background: The faecal immunochemical test (FIT) is used in colorectal cancer (CRC) screening and for the detection of advanced colorectal neoplasia (AN) in symptomatic patients, but its accuracy could be improved. Our objective was to assess the impact of proton pump inhibitors (PPI) on the accuracy of the FIT in the detection of AN, namely advanced colorectal adenoma and CRC., Methods and Findings: We performed a prospective study of 1002 individuals referred for a diagnostic colonoscopy at Bellvitge University Hospital from September 2011 through to October 2012. An exhaustive interview was performed by a gastroenterologist, prescription drug dispensing database was reviewed and the patient was given a FIT prior to colonoscopy. The positivity threshold of FIT used was ≥ 20 μg Hb/g feces and the main outcome was AN. AN was detected in 13.2% (133) of patients. The accuracy of FIT for detecting AN in the PPI users and non-PPI users were: sensitivity 43.0% vs 65.6%, P = 0.009; specificity 86.9% vs 92.3%, P = 0.010; and, predictive positive value 34.4% vs 55.5%, P = 0.007, respectively. In multivariate analysis, adjusting for potential confounders, PPIs were associated with false positives in AN detection by FIT (OR 1.63 CI 95% 1.02-2.59, P < 0.037). The ROC curve for the FIT in the detection of AN in the PPI users and non-PPI users was 0.68 (CI 95% 0.61-0.76) and 0.85 (CI 95% 0.79-0.90)., Conclusions: PPI therapy reduces the accuracy of FIT for detecting AN in symptomatic patients., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2018
- Full Text
- View/download PDF
27. Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study.
- Author
-
Ibáñez-Sanz G, Díez-Villanueva A, Vilorio-Marqués L, Gracia E, Aragonés N, Olmedo-Requena R, Llorca J, Vidán J, Amiano P, Nos P, Fernández-Tardón G, Rada R, Chirlaque MD, Guinó E, Dávila-Batista V, Castaño-Vinyals G, Pérez-Gómez B, Mirón-Pozo B, Dierssen-Sotos T, Etxeberria J, Molinuevo A, Álvarez-Cuenllas B, Kogevinas M, Pollán M, and Moreno V
- Subjects
- Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Case-Control Studies, Colorectal Neoplasms prevention & control, Dietary Supplements, Female, Humans, Male, Middle Aged, Chondroitin Sulfates administration & dosage, Colorectal Neoplasms epidemiology, Glucosamine administration & dosage
- Abstract
A safe and effective colorectal cancer (CRC) chemoprevention agent remains to be discovered. We aim to evaluate the association between the use of glucosamine and/or chondroitin sulphate and risk of colorectal cancer (CRC) in the MCC-Spain study, a case-control study performed in Spain that included 2140 cases of CRC and 3950 population controls. Subjects were interviewed on sociodemographic factors, lifestyle, family and medical history and regular drug use. Adjusted odds ratios and their 95% confidence intervals were estimated. The reported frequency of chondroitin and/or glucosamine use was 2.03% in controls and 0.89% in cases. Users had a reduced risk of CRC (OR: 0.47; 95% CI: 0.28-0.79), but it was no longer significant when adjusted for NSAID (nonsteroidal anti-inflammatory drugs) use (OR: 0.82; 95% CI: 0.47-1.40). A meta-analysis with previous studies suggested a protective effect, overall and stratified by NSAID use (OR: 0.77; 95% CI: 0.62-0.97). We have not found strong evidence of an independent preventive effect of CG on CRC in our population because the observed effects of our study could be attributed to NSAIDs concurrent use. These results merit further research due to the safety profile of these drugs.
- Published
- 2018
- Full Text
- View/download PDF
28. Corrigendum: Risk Model for Colorectal Cancer in Spanish Population Using Environmental and Genetic Factors: Results from the MCC-Spain study.
- Author
-
Ibáñez-Sanz G, Díez-Villanueva A, Alonso MH, Rodríguez-Moranta F, Pérez-Gómez B, Bustamante M, Martin V, Llorca J, Amiano P, Ardanaz E, Tardón A, Jiménez-Moleón JJ, Peiró R, Alguacil J, Navarro C, Guinó E, Binefa G, Fernández-Navarro P, Espinosa A, Dávila-Batista V, Molina AJ, Palazuelos C, Castaño-Vinyals G, Aragonés N, Kogevinas M, Pollán M, and Moreno V
- Published
- 2017
- Full Text
- View/download PDF
29. Risk Model for Colorectal Cancer in Spanish Population Using Environmental and Genetic Factors: Results from the MCC-Spain study.
- Author
-
Ibáñez-Sanz G, Díez-Villanueva A, Alonso MH, Rodríguez-Moranta F, Pérez-Gómez B, Bustamante M, Martin V, Llorca J, Amiano P, Ardanaz E, Tardón A, Jiménez-Moleón JJ, Peiró R, Alguacil J, Navarro C, Guinó E, Binefa G, Fernández-Navarro P, Espinosa A, Dávila-Batista V, Molina AJ, Palazuelos C, Castaño-Vinyals G, Aragonés N, Kogevinas M, Pollán M, and Moreno V
- Subjects
- Case-Control Studies, Gene Frequency, Humans, Models, Statistical, Polymorphism, Single Nucleotide, Risk Assessment, Spain epidemiology, Colorectal Neoplasms epidemiology, Colorectal Neoplasms genetics, Environmental Exposure
- Abstract
Colorectal cancer (CRC) screening of the average risk population is only indicated according to age. We aim to elaborate a model to stratify the risk of CRC by incorporating environmental data and single nucleotide polymorphisms (SNP). The MCC-Spain case-control study included 1336 CRC cases and 2744 controls. Subjects were interviewed on lifestyle factors, family and medical history. Twenty-one CRC susceptibility SNPs were genotyped. The environmental risk model, which included alcohol consumption, obesity, physical activity, red meat and vegetable consumption, and nonsteroidal anti-inflammatory drug use, contributed to CRC with an average per factor OR of 1.36 (95% CI 1.27 to 1.45). Family history of CRC contributed an OR of 2.25 (95% CI 1.87 to 2.72), and each additional SNP contributed an OR of 1.07 (95% CI 1.04 to 1.10). The risk of subjects with more than 25 risk alleles (5
th quintile) was 82% higher (OR 1.82, 95% CI 1.11 to 2.98) than subjects with less than 19 alleles (1st quintile). This risk model, with an AUROC curve of 0.63 (95% CI 0.60 to 0.66), could be useful to stratify individuals. Environmental factors had more weight than the genetic score, which should be considered to encourage patients to achieve a healthier lifestyle.- Published
- 2017
- Full Text
- View/download PDF
30. Prescription drugs associated with false-positive results when using faecal immunochemical tests for colorectal cancer screening.
- Author
-
Ibáñez-Sanz G, Garcia M, Rodríguez-Moranta F, Binefa G, Gómez-Matas J, Domènech X, Vidal C, Soriano A, and Moreno V
- Subjects
- Aged, Anus Diseases complications, Colonoscopy methods, Cross-Sectional Studies, False Positive Reactions, Feces chemistry, Female, Hemoglobins analysis, Humans, Logistic Models, Male, Middle Aged, Multivariate Analysis, Occult Blood, Prescription Drugs isolation & purification, Risk Factors, Spain, Colorectal Neoplasms diagnosis, Early Detection of Cancer methods, Mass Screening methods, Proton Pump Inhibitors isolation & purification
- Abstract
Background: The most common side effect in population screening programmes is a false-positive result which leads to unnecessary risks and costs., Aims: To identify factors associated with false-positive results in a colorectal cancer screening programme with the faecal immunochemical test (FIT)., Methods: Cross-sectional study of 472 participants with a positive FIT who underwent colonoscopy for confirmation of diagnosis between 2013 and 2014. A false-positive result was defined as having a positive FIT (≥20μg haemoglobin per gram of faeces) and follow-up colonoscopy without intermediate/high-risk lesions or cancer., Results: Women showed a two-fold increased likelihood of a false-positive result compared with men (adjusted OR, 2.3; 95%CI, 1.5-3.4), but no female-specific factor was identified. The other variables associated with a false-positive result were successive screening (adjusted OR, 1.5; 95%CI, 1.0-2.2), anal disorders (adjusted OR, 3.1; 95%CI, 2.1-4.5) and the use of proton pump inhibitors (adjusted OR, 1.8; 95%CI, 1.1-2.9). Successive screening and proton pump inhibitor use were associated with FP in men. None of the other drugs were related to a false-positive FIT., Conclusion: Concurrent use of proton pump inhibitors at the time of FIT might increase the likelihood of a false-positive result. Further investigation is needed to determine whether discontinuing them could decrease the false-positive rate., (Copyright © 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
31. Endoscopic band ligation without resection in selected patients for small and superficial upper gastrointestinal tract lesions.
- Author
-
Ibáñez-Sanz G, Gornals JB, Rivas L, Salord S, Paúles MJ, Botargues JM, and Galán M
- Subjects
- Aged, Aged, 80 and over, Female, Gastrointestinal Neoplasms surgery, Humans, Ligation, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Endoscopy, Gastrointestinal methods, Gastrointestinal Diseases surgery, Upper Gastrointestinal Tract surgery
- Abstract
Background and Aim: The aim of this study was to evaluate the efficacy of endoscopic band ligation (EBL) in carefully selected patients who would benefit from this method of resection., Methods: Patients with early upper gastrointestinal and small (< 15 mm) lesions treated with EBL (Duette® Multi-Band Mucosectomy) were prospectively recruited and retrospectively analyzed between 2010 and 2015. All cases were discussed in a multidisciplinary cancer committee and it was concluded that, owing to patient conditions, surgery was not possible and that not conducting histology would not change the clinical management. A first endoscopic control with biopsies was planned at 4-8 weeks. If there was no persistence of the lesion, new controls were programmed at 6 and 12 months., Results: The group (n = 12) included 5 esophagus lesions (adenosquamous carcinoma, n = 1; carcinoma squamous, n = 2; adenocarcinoma, n = 2); 4 gastric lesions (high grade dysplasia, n = 1; adenocarcinoma, n = 2; neuroendocrine tumor [NET], n = 1), and 3 duodenal lesions (NETs) (n = 3). The mean tumor diameter was 9.6 ± 2.8 mm (range 4-15). Only one minor adverse event was described. At first follow-up (4-8 weeks), there was 91.6% and 75% of endoscopic and histological remission, respectively. At 6-month follow-up there was 70% of both endoscopic remission and negative biopsies. And at 12 months, there was 100% and 75% of endoscopic and histological remission, respectively. Persisting lesions were T1 cancers. The median follow-up was 30.6 months., Conclusion: EBL without resection is an easy and safe technique that should be considered in patients with multiple morbidities and small superficial UGI lesions.
- Published
- 2016
- Full Text
- View/download PDF
32. Spontaneous intramural esophageal dissection: an unusual onset of eosinophilic esophagitis.
- Author
-
Ibáñez-Sanz G, Rodríguez-Alonso L, and Romero NM
- Subjects
- Adult, Anti-Bacterial Agents therapeutic use, Endoscopy, Gastrointestinal, Humans, Male, Proton Pump Inhibitors therapeutic use, Tomography, X-Ray Computed, Eosinophilic Esophagitis diagnostic imaging, Eosinophilic Esophagitis therapy, Esophagus diagnostic imaging
- Abstract
A 35-year-old man, with a history of rhinitis, eczema and a dubious achalasia was admitted due to chest pain and sialorrhea. Upper endoscopy showed a little hole and a narrowing of the distal esophagus. A CT-scan with oral contrast exposed a discontinuity of the lumen of the middle third of the esophagus and a dissection of submucosal space 16 cm long. The patient recovered after parenteral nutrition. After four months, an esophageal endoscopic showed transient whitish exudates, longitudinal furrows and esophageal lacerations. The biopsies illustrated significant eosinophilic inflammation, eosinophilic microabscesses and basal cell hyperplasia.
- Published
- 2016
33. Endoscopic radiofrequency ablation for APC refractory gastric antral vascular ectasia using the HALO90 system in a kidney transplant candidate.
- Author
-
Ibáñez-Sanz G, Rivas L, Melilli E, Guardiola J, Baliellas C, and Gornals JB
- Subjects
- Argon Plasma Coagulation, Gastric Antral Vascular Ectasia complications, Gastric Antral Vascular Ectasia diagnostic imaging, Gastroscopy, Humans, Kidney Failure, Chronic surgery, Kidney Transplantation, Male, Middle Aged, Catheter Ablation instrumentation, Gastric Antral Vascular Ectasia surgery, Kidney Failure, Chronic complications
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.